Details for Patent: 10,414,748

Which drugs does patent 10,414,748 protect, and when does it expire?

Patent 10,414,748 protects DAURISMO and is included in one NDA.

This patent has thirty-seven patent family members in twenty-four countries.

Summary for Patent: 10,414,748

Title:	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyan- ophenyl)urea maleate
Abstract:	This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyan- ophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Inventor(s):	Seadeek; Christopher Scott (West Lafayette, IN)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	15/567,433
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,414,748

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-001	Nov 21, 2018		RX	Yes	No			Y	Y
Pfizer	DAURISMO	glasdegib maleate	TABLET;ORAL	210656-002	Nov 21, 2018		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 10,414,748

PCT Information
PCT Filed	April 13, 2016	PCT Application Number:	PCT/IB2016/052107
PCT Publication Date:	October 27, 2016	PCT Publication Number:	WO2016/170451

International Family Members for US Patent 10,414,748

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	104391
Australia	2016251940
Brazil	112017021075